ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

VIRX Viracta Therapeutics Inc

0.8102
-0.0298 (-3.55%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Viracta Therapeutics Inc VIRX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.0298 -3.55% 0.8102 06:16:11
개장가 저가 고가 종가 전일 종가
0.8212 0.80 0.84 0.8102 0.84
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
15/04/202421:00GLOBEViracta Therapeutics Announces Positive Topline Nana-val..
01/04/202421:30GLOBEViracta Therapeutics to Present Topline Nana-val Results..
08/03/202407:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/03/202406:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/03/202406:12EDGAR2Form 8-K - Current report
08/03/202406:05GLOBEViracta Therapeutics Reports Fourth Quarter and Full Year..
29/02/202422:00GLOBEViracta Therapeutics Announces Completion of Second-Stage..
28/02/202410:40EDGAR2Form 144 - Report of proposed sale of securities
28/02/202409:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202409:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/02/202411:04EDGAR2Form SC 13G - Statement of acquisition of beneficial..
07/02/202406:05GLOBEViracta Therapeutics to Present at the Oppenheimer 34th..
04/01/202422:00GLOBEViracta Therapeutics Provides Clinical Update and Outlook..
12/12/202322:00GLOBEViracta Therapeutics Announces Orphan Drug Designation..
05/12/202306:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202322:30GLOBEViracta Therapeutics Announces Interim Data from Phase 1b/2..
29/11/202309:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202309:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202307:30EDGAR2Form 8-K - Current report
10/11/202306:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:30EDGAR2Form 8-K - Current report
09/11/202322:30GLOBEViracta Therapeutics Reports Third Quarter 2023 Financial..
08/11/202306:15GLOBEViracta Therapeutics to Present at Upcoming Investor..
04/10/202320:01EDGAR2Form 8-K - Current report
04/10/202320:00GLOBEViracta Therapeutics to Host R&D Day Highlighting Nana-val..
05/09/202322:00GLOBEViracta Therapeutics to Host R&D Day on October 4, 2023
30/08/202307:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/08/202307:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/08/202305:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/08/202305:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/08/202305:05GLOBEViracta Therapeutics Announces New Employment Inducement..
17/08/202306:58EDGAR2Form 3 - Initial statement of beneficial ownership of..
15/08/202305:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/08/202321:02EDGAR2Form 8-K - Current report
14/08/202321:00GLOBEViracta Therapeutics Reports Second Quarter 2023 Financial..
08/08/202321:30GLOBEViracta Therapeutics Announces Publication in Blood Advances..
07/08/202320:36EDGAR2Form 8-K - Current report
07/08/202320:30GLOBEViracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D...
28/06/202321:00GLOBEViracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves..
01/06/202305:15GLOBEViracta Therapeutics to Present at the Jefferies Healthcare..
12/05/202305:05GLOBEViracta Therapeutics to Present at the RBC Capital Markets..
09/05/202305:05GLOBEViracta Therapeutics Reports First Quarter 2023 Financial..

최근 히스토리

Delayed Upgrade Clock